Skip to content

13F-HR filed by Svennilson Peter

Svennilson Peter filed this 13F-HR for the quarter ended 2020-03-31, filed 2020-05-07, with 6 holding rows worth $789,930,000.

Accession
0001606074-20-000005
Filed
2020-05-07
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2020

A holdings report, 10 entries on the cover page, a total value of $789,930,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $789,930,000 with VALUE read as thousands by filing date, 13F file number 028-16412. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
NGM BIOPHARMACEUTICALS INC62921N105COM17,323,144$213,594,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock6,051,376$190,195,000thousands by filing date
REVOLUTION MEDICINES INC COM76155X100Stock7,977,384$174,784,000thousands by filing date
RAPT THERAPEUTICS INC75382E109COM6,777,151$144,151,000thousands by filing date
ARCUS BIOSCIENCES INC03969F109COM3,540,850$49,147,000thousands by filing date
GRITSTONE BIO INC39868T105COM3,102,934$18,059,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001606074-20-000005this filing2020-05-07acceptance time not in the bulk data set